The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price surges in Tonix Pharmaceuticals (NASDAQ: TNXP) and Lexeo Therapeutics (NASDAQ: LXEO). The biotech industry is known for its volatile price swings, often influenced by clinical trial results and regulatory decisions. Tonix and Lexeo recently experienced significant single-day stock gains as part of a series of green days, sparking investor interest and exemplifying this volatility.
These surges raise the question of whether they are temporary or represent potential long-term value. Are these "biotech bargains" genuine opportunities or simply moments of market enthusiasm?
